02442nam a22004331i 4500 000708945 CaToSAGE 20240202172917.0 20211115153915.7 m o d cr un||||||||| 211115s2020 enka fo 000 0 eng d NEZPRACOVANÝ IMPORT 9781529795080 (ebook) : No price (OCoLC)1286093572 CaToSAGE eng rda pn CaToSAGE UtOrBLW Q180.55.G7 K56 2020 001.440943 Kinkead, Gwen, 1951- author. Cystic Fibrosis Foundation : balancing venture philanthropy with treatment / Gwen Kinkead. London : Yale School of Management, 2020. 1 online resource : illustrations. text txt rdacontent computer c rdamedia online resource cr rdacarrier SAGE Business cases Originally Published InKinkead, G. (2020). Cystic Fibrosis Foundation: Balancing Venture Philanthropy with Treatment. 20-032-15. New Haven, CT: Yale School of Management, Yale University. In 2020, Dr. Michael Boyle, the new president and CEO of the Cystic Fibrosis Foundation of Bethesda, Maryland, was in a fortunate position. He commanded a larger endowment than the biggest national medical charities, including the American Red Cross, the American Heart Association and the American Cancer Society: $4.2 billion, eleven times budgeted 2020 expenses. The money was earned through partnering with industry partners to create new drugs to treat Cystic Fibrosis, which have changed the condition from being fatal to a manageable disease and earned the found 3.7 billion dollars in revenue. However, these drugs fall short of being a cure and Dr Boyle must now decide how to spend the endowment. Should he invest substantial resources into finding a cure or focus more on helping those who have cystic fibrosis at the moment? Description based on XML content. elektronické knihy fd186907 czenas electronic books eczenas Endowment of research. SAGE Business cases. SAGE Knowledge https://sk.sagepub.com/cases/cystic-fibrosis-foundation-balancing-venture-philanthropy-treatment Plný text SBC EB NEPOSILAT EB